论文部分内容阅读
OncoMed公司宣布其登西珠单抗(demcizumab)一线治疗胰腺癌的Ⅰb期临床试验资料更新。Ⅰb期临床试验共入选56名胰腺癌患者,首先24名患者接受此药和吉西他滨(gemcitabine)治疗,协议修订后其余32名患者接受缩短登西珠单抗给药期(70 d)和新标准的吉西他滨加紫杉醇蛋白质结合颗粒注射悬液治疗。结果14人获得部分有效反应,11名病情稳定,临床受益率为89%。三药复方一般耐受良好,最常见不良反应是
OncoMed Announces Update of Phase 1b Clinical Trial of its First-Line Treatment of Pancreatic Cancer with Dexcitizumab. In Phase Ib clinical trials, 56 patients with pancreatic cancer were enrolled. Twenty-four patients were initially treated with gemcitabine and the drug. The remaining 32 patients were treated with the shortened duration of dexcyliation (70 d) and the new standard Gemcitabine Plus Paclitaxel-Protein-Coated Granules for Injection Suspension Treatments. Results 14 people were partially effective response, 11 were stable, the clinical benefit rate was 89%. The three drug compound generally well-tolerated, the most common adverse reactions are